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See related article on page 45. Lung transplantation (LTX) is an effective form of palliative therapyfor a variety of end-stage lung diseases, but access to LTX isseverely limited by a scarcity of suitable donors. Fewer than 900LTX procedures are performed annually in the United States al-though over 4000 patients are currently listed for LTX.1 In part,because of the scarcity of donors, strict listing criteria for potential
LTX recipients are espoused.2 Current malignancy is considered an absolute con-
traindication to LTX, because of the concern that poor prognosis due to the
malignancy and possible acceleration of tumor growth secondary to immunosup-
pression would surely jeopardize long-term survival. As deaths on the waiting list
increase, there is growing pressure not to squander such a scarce and precious
resource as transplantable lungs.
In this issue of the Journal, Zorn and associates3 challenge this paradigm by
reporting their experience with LTX for a subset of patients with bronchioalveolar
carcinoma (BAC). They tested the hypothesis that total lung replacement could be
curative for the diffuse form of BAC by transplanting 9 patients presumed to have
this diagnosis. One of the 9 was found to have adenocarcinoma, not BAC, after lung
replacement, and so was not included in the Kaplan-Meier survival analysis.
Arguably, by intention-to-treat analysis, this patient should have been included,
because if LTX is to be recommended as a therapy for BAC, then this misdiagnosis
would presumably occur with a similar frequency as it did in this report. This
inclusion would not change the provocative finding that survival of patients with
BAC who underwent LTX was similar to that of patients having LTX for other
indications.
The fact that patients with BAC did just as well as patients with other indications
for LTX is just as much a sad commentary on the long-term results of LTX as it is
a sterling recommendation for this strategy as a therapy for BAC. Zorn and
associates titillate with their impressive survival statistics and aggressive surgical
approach to disease recurrence, but leave the reader to speculate just how many
patients with lung cancer were evaluated to select the 9 study patients. How realistic
is this option for those with diffuse BAC? How many patients were eliminated
because of metastatic disease or mediastinal lymph node involvement? Two of their
9 patients who had LTX had positive N2 nodes at operation (although only 1 of
these patients had “true” BAC). The recurrence rate was disappointing, with 6 of 8
patients having recurrent disease, and many of their patients ultimately died of BAC.
Thus, it would appear that their hypothesis was not true; LTX is not a “curative”
strategy for BAC. However, LTX is not a curative therapy for any end-stage lung
disease. As a form of palliation, LTX for selected patients with BAC may have
merit, based on this initial report in a small number of presumably highly selected
patients.
The authors report that they have abandoned LTX for BAC because of the high
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recurrence rate and the increasing wait time for transplan-
tation. Despite the recurrence rate, however, excellent pal-
liation of incapacitating dyspnea was achieved for a time in
virtually all patients. Should LTX be performed for diseases
that recur? At first blush, the intuitive answer is a resound-
ing “NO!” But LTX is routinely offered to patients with
end-stage lung disease due to sarcoidosis and lymphangio-
leiomyomatosis (LAM); both diseases recur in LTX recip-
ients.4,5 Alpha-1 antitrypsin deficiency emphysema would
presumably recur in transplanted lungs if patients with this
disease survived long enough after LTX. Because LTX is
really not a cure for any lung disease, we must ask our-
selves: what is the measure of success among LTX recipi-
ents? If one patient is just as likely to survive as long as
another, does it matter whether the recipient diagnosis is
malignant? And we must address the thorny issue of who
should be offered a lung transplant, particularly given the
vexing shortage of suitable donor lungs.
The Department of Health and Human Services has
required that United Network for Organ Sharing (UNOS)
organ allocation policies place less importance on waiting
time and geography, and consider equity and utility in
amending organ allocation algorithms. The ideal would be
to attempt to provide organs to those more at risk of death,
balanced by the desire not to waste organs by transplanting
them into hopelessly ill individuals with significantly com-
promised opportunity for survival. The Lung Allocation
subcommittee of the UNOS Thoracic Organ Committee has
made substantial progress on identifying factors associated
with increased risk of death on the UNOS LTX waiting list,6
as well as factors associated with an increased risk of death
within 1 year of LTX.7 Using this and similar information,
the UNOS Thoracic Organ Committee hopes to recommend
a lung distribution algorithm that places more importance
on saving and extending lives rather than on the ability to
survive a long wait with lung disease. Perhaps if such an
algorithm were in place, LTX for BAC would be a practical
option because waiting time would no longer be the prin-
cipal variable in lung allocation.
Surely one of the most fascinating aspects of the report
by Zorn and colleagues is what it potentially implies about
the etiology of BAC. In an earlier publication, this group
suggested that recurrence of BAC might be related to tumor
cells left behind in the large airway that later migrated to the
alveolar spaces to reappear as BAC recurrence.8 Indeed,
aerogenous spread has been postulated as an explanation for
the observation that approximately 60% of recurrences in
cases of resected BAC involve only the remaining lung.9
Others postulate that BAC is the result of a stimulus (pos-
sibly viral) that has a propensity to cause multifocal sites of
pulmonary involvement. In cases of resected BAC, only
about 40% of all patients experience a recurrence, and
approximately 40% of the recurrences involve distant sites.9
It is striking that recurrence was seen in 75% of patients
who had lung transplantation for BAC, and that all of these
involved only the lung. The higher incidence of recurrence
among patients with BAC undergoing LTX may be because
these patients had more extensive disease than patients who
underwent resection alone. However, that would not explain
the exclusive localization of recurrences to the lung. One
could postulate that immunosuppression might contribute to
a higher incidence of cancer recurrence, but this should lead
to a higher recurrence rate elsewhere in the body as well.
A critical question is whether the malignant cells in the
recurrent BAC are of recipient or donor origin. If the
mechanism of recurrence involves aerogenous spread, the
BAC cells should have the genotype of the recipient and be
distinct from the donor. On the other hand, if the “recur-
rence” is a manifestation of a continued stimulus for alve-
olar proliferation that is now acting on the transplanted
alveolar cells, then the genotype of the “recurrent” BAC
should be the same as that of the donor.
The fact that the histologic appearance of the recurrent
BAC was similar to the primary BAC before transplant does
not address this issue adequately. In their earlier report, the
authors used DNA polymorphisms10 from tissue specimens
to attempt to identify the origin of the BAC and concluded
that the recurrent BAC in 3 of their patients appeared to be
of recipient genotype.8 However, the method of sampling of
tumor was relatively crude. And the use of reverse tran-
scriptase–polymerase chain reaction raises the possibility
that contamination of the tumor cells with nonmalignant
recipient leukocytes or alveolar macrophages might falsely
identify tumor as being of recipient origin. Indeed, close
inspection of the data in their earlier report suggests that
their 3 patients showed both donor and recipient DNA in the
recurrent tumor. More sophisticated techniques for tissue
sampling, such as laser capture microdissection,11 might
answer the question definitively. Perhaps HLA class I anti-
gens on tumor cells could be demonstrated by immunohis-
tochemistry. The authors must make an effort to establish
with more certainty whether recurrent BAC cells are of
donor or recipient origin.
If recurrent BAC cells are of donor origin (which ap-
pears less likely from the DNA evidence), it would provide
strong evidence that diffuse BAC is a response of alveolar
epithelial cells to a stimulus that arises outside of the lung
parenchyma. But what if the earlier analysis is correct and
recurrent BAC cells are of recipient origin? How reasonable
is it to postulate that BAC cells spread by aerogenous route
when all lung tissue was removed? Did the cells crawl out
of the alveoli and lie dormant for years before recurrence?
Where? Did they hide somewhere distant and migrate back
to the lung years later? If so, why did these patients not have
metastases where the cells “hid away?”
The evidence presented in this small series of patients
Egan and Detterbeck Editorials
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 1 21
suggests that BAC is a systemic disease manifested in the
alveolar epithelium, or that BAC is a manifestation of a
systemic stimulus that results in alveolar proliferation. This
would explain the high rate of recurrence after LTX, al-
though it is not clear why the incidence of recurrence or its
distribution would be different from in patients who under-
went resection of BAC without LTX. Recurrence of BAC
after LTX may be virtually inevitable because the stimulus
to undergo malignant transformation is still present in the
recipient. Pulmonary alveolar macrophages may be the cul-
prits, or some other marrow derived cells that interact with
the pulmonary epithelium. Perhaps the malignancy is a
disease of marrow-derived pulmonary epithelial stem cells
that require a “hospitable” site to migrate to and undergo
malignant transformation. The BAC LTX recipients who
have so far avoided recurrence may have been transplanted
with a genotype that has protected them from the stimulus to
malignant transformation or made the alveoli inhospitable
to recipient malignant stem cells.
Presumably LTX “starts the clock” again on the prolif-
eration of the malignant cells. Does immunosuppression
affect the natural history of BAC? Is time to recurrence and
death altered by immunosuppression, or is time to recur-
rence simply a manifestation of latency for malignant cells
to reach a critical mass to become obvious clinically?
Diffuse BAC is fortunately an unusual disease, but even
if it represents only 3% of lung cancer cases, as reported by
Zorn and associates, that would amount to almost 5000
cases a year in the United States. However, approximately
60% of these cases occur as a solitary nodule, while the rest
involve infiltrative, multifocal, or diffuse presentations of
the disease.9 Thus, 2000 BAC patients might be considered
for LTX. Given the current shortage of donor lungs, LTX is
currently not a practical therapeutic option. However, if
LTX is feasible using lungs retrieved from circulation-
arrested non–heart beating donors,12 then an unlimited sup-
ply of donor lungs might make LTX a reasonable option for
all of these unfortunate patients.
So what are the ABCs? Perhaps Alveolar epithelial cells
undergo malignant transformation in response to an un-
known (Anonymous) stimulus that arises outside of the
lung. Or, Bronchioalveolar carcinoma may not be a lung
disease per se, but rather a manifestation of an Abnormality
in another Cell population. Lung transplant for BAC is, as
the authors point out, Controversial, but it is Certainly not
Crazy, based on the encouraging data from their small
series.
We acknowledge the assistance of Dr W. Funkhouser (Depart-
ment of Pathology, University of North Carolina) and the editorial
assistance of Margaret Cloud.
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